Combating disease with cryptic metabolites
The Cryptyx Bioscience drug discovery platform provides a rapid, efficient approach for activating silent biosynthetic gene clusters and unearthing potential leads that cannot be accessed with extant technologies.
We develop novel disease therapies
Many clinically used antibiotics and other medicines are derived from bacterial small molecules produced by dedicated biosynthetic gene clusters (BGCs). Recent investigations, however, have shown that these are the tip of the iceberg and that the majority of BGCs encoded in microbial genomes are transcriptionally silent or "cryptic." Identifying the triggers that lead to activation of these silent clusters has the potential to greatly expand our repertoire of therapeutic molecules.
Unlike nearly all existing methods developed to activate silent BGCs, our platform does not require complex genetic, cloning, or culturing procedures, can be used with both sequenced and unsequenced bacteria, and reliably reports on the bioactivity of the cryptic metabolite. We are currently using our technology platform to advance novel therapies for bacterial and viral pathogens and are in the process of expanding our R&D to oncology.
Partnerships
Leverage our platform
We offer several ways for clients to work with us and our platform to bring cryptic metabolite drug leads to market.
HiTES on demand
Our HiTES platform is versatile and can be applied to any microorganism to either enhance production of known natural products or induce entirely new ones. We offer HiTES for on-demand use on any microbe of choice.
